| Date | Title | Description |
| 20.03.2026 | Elicera Therapeutics Announces Swedish Cancer Society’s Senior Investigator Award to Chief Development Officer Di Yu | Elicera Therapeutics Announces Swedish Cancer Society’s Senior Investigator Award to Chief Development Officer Di Yu
Fri, Mar 20, 2026 08:53 CET Report this content
Gothenburg, March 20, 2026 – Elicera Therapeutics AB (publ), a clinical sta... |
| 11.03.2026 | Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate | Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate
Wed, Mar 11, 2026 10:53 CET Report this content
Gothenburg, March 11, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a cl... |
| 10.03.2026 | Elicera Therapeutics’ Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden) | Elicera Therapeutics’ Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)
Tue, Mar 10, 2026 09:41 CET Report this content
Gothenburg, March 10, 2026 – Elicera Therapeu... |
| 06.03.2026 | Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients | Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients
Fri, Mar 06, 2026 08:30 CET Report this content
... |
| 27.02.2026 | Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway | Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway
Fri, Feb 27, 2026 08:30 CET Report this content
Gothenburg, February 27,... |
| 18.02.2026 | Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference | Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference
Wed, Feb 18, 2026 13:57 CET Report this content
Gothenburg, February 18, 2026 – Elicera Therapeutics AB (publ), a clini... |
| 13.02.2026 | Elicera Therapeutics AB (publ) Year-End 1 January – 31 December 2025 | Elicera Therapeutics AB (publ) Year-End 1 January – 31 December 2025
Fri, Feb 13, 2026 08:20 CET Report this content
Fourth quarter (October-December 2025) Operating loss amounted to o SEK -7,129,626 (-2,911,958). Loss for the period amount... |
| 11.02.2026 | Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study | Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study
Wed, Feb 11, 2026 14:32 CET Report this content
Gothenburg... |
| 22.01.2026 | Elicera Therapeutics’ CSO invited to present at multiple scientific conferences | Elicera Therapeutics’ CSO invited to present at multiple scientific conferences
Thu, Jan 22, 2026 09:43 CET Report this content
Gothenburg, January 22, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company de... |
| 09.01.2026 | Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors | Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors
Fri, Jan 09, 2026 13:53 CET Report this content... |
| 23.12.2025 | Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)
Tue, Dec 23, 2025 08:58 CET Report this content
Correction: The press release published on October 23, 202... |
| 14.11.2025 | Elicera Therapeutics AB (publ) Interim 1 January – 30 September 2025 | Elicera Therapeutics AB (publ) Interim 1 January – 30 September 2025
Fri, Nov 14, 2025 08:19 CET Report this content
Third quarter (July-September 2025) Operating loss amounted to SEK 146,689 (-2,697,267). Loss for the period amounted to SE... |
| 13.11.2025 | Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research | Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research
Thu, Nov 13, 2025 08:30 CET Report this content
Gothenburg, November... |
| 23.10.2025 | Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)
Thu, Oct 23, 2025 16:01 CET Report this content
Elicera Therapeutics AB (publ) hereby announces a change of Certified ... |
| 19.09.2025 | Elicera clarifies status of the iTANK-platform patent application in the U.S. | Elicera clarifies status of the iTANK-platform patent application in the U.S.
Fri, Sep 19, 2025 15:49 CET Report this content
Gothenburg, August 25, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company devel... |
| 29.08.2025 | Elicera Therapeutics AB (publ) Interim 1 January – 30 June 2025 | Elicera Therapeutics AB (publ) Interim 1 January – 30 June 2025
Fri, Aug 29, 2025 08:18 CET Report this content
Second quarter (April-June 2025) Operating loss amounted to SEK -2,892,341 (-5,841,409). Loss for the period amounted to SEK -2,... |
| 25.08.2025 | Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy
Mon, Aug 25, 2025 13:30 CET Report this content
Gothenburg, August 25, 2025 – E... |
| 25.08.2025 | Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee’s Assessment in Cohort 2 | Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee’s Assessment in Cohort 2
Mon, Aug 25, 2025 10:43 CET Report this content
Gothenburg, August 25, 2025 – Elicera Therapeutics... |
| 15.05.2025 | Elicera Therapeutics AB (publ) Interim 1 January – 31 March 2025 | Elicera Therapeutics AB (publ) Interim 1 January – 31 March 2025
Thu, May 15, 2025 08:17 CET Report this content
First quarter (January-March 2025) Operating loss amounted to SEK -8,069,404 (-5,433,422). Loss for the period amounted to SEK ... |
| 12.04.2025 | Elicera Therapeutics and DUG Foodtech: Pioneering Paths in Cancer Treatment and Sustainable Beverages | In the ever-evolving landscape of biotechnology and food innovation, two companies stand out: Elicera Therapeutics and DUG Foodtech. Each is carving a niche in their respective fields, driven by innovation and a commitment to sustainability... |
| 10.04.2025 | Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee’s assessment of cohort 1 | Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee’s assessment of cohort 1
Thu, Apr 10, 2025 14:44 CET Report this content
Gothenburg, April 10, 2025 – Elicera T... |
| 20.03.2025 | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2 | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2
Thu, Mar 20, 2025 12:29 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION I... |
| 13.03.2025 | Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters | Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters
Thu, Mar 13, 2025 11:27 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DIS... |
| 07.03.2025 | The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025 | The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025
Fri, Mar 07, 2025 08:02 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY... |
| 01.03.2025 | Elicera Therapeutics: A Financial Leap with Warrants TO2 | Elicera Therapeutics is making waves in the biotech world. The company has set the exercise price for its series TO2 warrants at SEK 1.85. This price is a key piece of the puzzle, unlocking potential funding and growth for the company. The ... |
| 28.02.2025 | Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics
Fri, Feb 28, 2025 09:45 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ... |
| 28.02.2025 | Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics
Fri, Feb 28, 2025 11:46 CET Report this content
Correction: In the previous press release, the number of TO2 in the table was inc... |
| 25.02.2025 | The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85 | The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85
Tue, Feb 25, 2025 08:29 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECT... |
| 25.02.2025 | Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million | Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million
Tue, Feb 25, 2025 13:01 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIR... |
| 12.02.2025 | Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme | Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme
Wed, Feb 12, 2025 09:43 CET Report this content
Gothenburg, February 12, 2025 – Elicera Therapeutics AB ... |
| 11.02.2025 | The Rise of Plant-Based Innovations: DUG Foodtech and Elicera Therapeutics Lead the Charge | In a world increasingly aware of climate change and health issues, innovation is the lifeblood of progress. Two companies, DUG Foodtech and Elicera Therapeutics, are stepping into the spotlight, each in their respective fields. One is trans... |
| 10.02.2025 | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans
Mon, Feb 10, 2025 13:30 CET Report this content
Gothenburg, February 10, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and g... |
| 03.02.2025 | Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2024 | Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2024
Mon, Feb 03, 2025 08:16 CET Report this content
Fourth quarter (October-December 2024) Operating profit/loss amounted to SEK -2,911,958 (-5,212,694). Loss for the p... |
| 21.01.2025 | Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference | Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference
Tue, Jan 21, 2025 08:30 CET Report this content
Gothenburg, January 21, 2025 – Elicera Therapeutics AB (publ), a clinical stag... |
| 13.01.2025 | Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors | Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors
Mon, Jan 13, 2025 11:15 CET Report this content
Gothenburg, January 13, 2025 – Elicera Therapeut... |
| 28.11.2024 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2024 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2024
Thu, Nov 28, 2024 08:15 CET Report this content
Third quarter (July-September 2024) Operating profit/loss amounted to SEK -2,697,267 (-5,149,440). Loss for the peri... |
| 05.11.2024 | Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma | Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma
Tue, Nov 05, 2024 12:36 CET Report this content
Gothenburg, November 5, 2024 – Elicera Therapeutics AB (publ), a clinical stage... |
| 25.10.2024 | Elicera Therapeutics and DUG Foodtech: A Dual Dive into Innovation and Investment | In the ever-evolving landscape of biotechnology and food technology, two companies stand out: Elicera Therapeutics and DUG Foodtech. Each is navigating its own path, yet both share a common goal: to innovate and thrive in their respective f... |
| 25.10.2024 | The Pulse of Innovation: A Look at Recent Developments in Life Sciences | In the world of life sciences, innovation is the lifeblood. Two recent reports highlight the dynamic landscape of this sector, showcasing growth, challenges, and the relentless pursuit of breakthroughs. The interim report from ADDvise Group... |
| 24.10.2024 | Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100 | Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100
Thu, Oct 24, 2024 08:42 CET Report this content
Gothenburg, October 24, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell... |
| 03.09.2024 | Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall | Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall
Tue, Sep 03, 2024 08:45 CET Report this content
Gothenburg, September 3, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and ge... |
| 29.08.2024 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2024 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2024
Thu, Aug 29, 2024 08:14 CET Report this content
Second quarter (April-June 2024)
Operating profit/loss amounted to SEK -5,841,409 (-4 466 286).
Loss for the period amoun... |
| 17.06.2024 | BioStock: Elicera teams up with China Medical University for cancer study | BioStock: Elicera teams up with China Medical University for cancer study
Mon, Jun 17, 2024 08:46 CET Report this content
Elicera Therapeutics has announced a new research collaboration with the Fourth Affiliated Hospital of China Medical U... |
| 11.06.2024 | Elicera Therapeutics enters a preclinical collaboration agreement with China Medical University for the development of ELC-201 | Elicera Therapeutics enters a preclinical collaboration agreement with China Medical University for the development of ELC-201
Tue, Jun 11, 2024 08:45 CET Report this content
Gothenburg, June 11, 2024 – Elicera Therapeutics AB (publ), a cli... |
| 29.05.2024 | BioStock: Elicera’s first clinical CAR T-Cell study CARMA set to begin | BioStock: Elicera’s first clinical CAR T-Cell study CARMA set to begin
Wed, May 29, 2024 10:04 CET Report this content
Elicera Therapeutics is on the brink of launching its first clinical CAR T-cell study, CARMA, which aims to generate cruc... |
| 27.05.2024 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2024 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2024
Mon, May 27, 2024 08:13 CET Report this content
First quarter (January-March 2024) Operating profit/loss amounted to SEK - 5,433,422 (-2,265,857). Loss for the period a... |
| 16.04.2024 | Elicera Therapeutics publishes the annual report for 2023 | Elicera Therapeutics publishes the annual report for 2023
Tue, Apr 16, 2024 18:09 CET Report this content
Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based ... |
| 28.03.2024 | Nomination committee proposes CMC specialist to Elicera’s board of directors | Nomination committee proposes CMC specialist to Elicera’s board of directors
Thu, Mar 28, 2024 12:16 CET Report this content
The Nomination Committee of Elicera Therapeutics AB (publ) proposes Sharon Longhurst as new board member. Sharon Lo... |
| 22.03.2024 | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB
Fri, Mar 22, 2024 08:13 CET Report this content
Elicera has entered into agreements with Mangold regarding the position as Certified Adviser ... |
| 11.03.2024 | Elicera Therapeutics announces outcome in rights issue | Elicera Therapeutics announces outcome in rights issue
Mon, Mar 11, 2024 17:59 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPA... |
| 04.03.2024 | Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue | Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue
Mon, Mar 04, 2024 14:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DI... |
| 23.02.2024 | The subscription period in Elicera Therapeutics’ rights issue of units starts today | The subscription period in Elicera Therapeutics’ rights issue of units starts today
Fri, Feb 23, 2024 08:06 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STAT... |
| 21.02.2024 | Elicera Therapeutics publishes prospectus in connection with rights issue of units | Elicera Therapeutics publishes prospectus in connection with rights issue of units
Wed, Feb 21, 2024 16:03 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATE... |
| 16.02.2024 | Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024 | Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024
Fri, Feb 16, 2024 10:14 CET Report this content
Gothenburg, February 16, 2024 – Elicera ... |
| 16.02.2024 | Elicera invites to investor meetings on February 28[th] and 29[th] 2024 | Elicera invites to investor meetings on February 28[th] and 29[th] 2024
Fri, Feb 16, 2024 08:30 CET Report this content
In connection with the upcoming rights issue in Elicera Therapeutics AB (publ) ("Elicera" or "the Company... |
| 13.02.2024 | Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023 | Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023
Tue, Feb 13, 2024 08:12 CET Report this content
Fourth quarter (October-December 2023) Operating profit/loss amounted to SEK -5,212,694 (-3,951,799). Loss for the p... |
| 09.02.2024 | Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma | Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma
Fri, Feb 09, 2024 08:30 CET Report this content
Gothenburg, February 9, 2024 – Elicera Therapeutics AB (pu... |
| 18.01.2024 | NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB | NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB
Thu, Jan 18, 2024 09:12 CET Report this content
The shareholders of Elicera Therapeutics AB, org.nr 556966-4955, (the “Company”), are hereby convened to an Extraordinary Gen... |
| 18.01.2024 | Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million | Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million
Thu, Jan 18, 2024 08:46 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE U... |
| 17.01.2024 | Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON | Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON
Wed, Jan 17, 2024 09:42 CET Report this content
Gothenburg, January 17, 2024 -... |
| 09.01.2024 | Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand | Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand
Tue, Jan 09, 2024 14:46 CET Report this content
Gothenburg, Januar... |
| 22.12.2023 | Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application | Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application
Fri, Dec 22, 2023 13:15 CET Report this content
Gothenburg, Dece... |
| 22.12.2023 | Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research | Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research
Fri, Dec 22, 2023 13:47 CET Report this content
Gothenburg, December 22, 2023 - Elicera Therapeutics ... |
| 30.11.2023 | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ) | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)
Thu, Nov 30, 2023 08:12 CET Report this content
Elicera Therapeutics has entered into agreements with Carnegie Investment Bank AB (p... |
| 14.11.2023 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Tue, Nov 14, 2023 08:11 CET Report this content
Third quarter (July-September 2023) Operating profit/loss totaled SEK -5,149,440 (-7,028,100). Loss for the period totale... |
| 31.10.2023 | Nomination Committee for Elicera therapeutics appointed | Nomination Committee for Elicera therapeutics appointed
Tue, Oct 31, 2023 08:10 CET Report this content
Gothenburg, October 31, 2023 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation... |
| 08.09.2023 | Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform | Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform
Fri, Sep 08, 2023 10:05 CET Report this content
Gothenburg, September 8, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage... |
| 29.08.2023 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Tue, Aug 29, 2023 08:10 CET Report this content
Second quarter (April-June 2023) Operating profit/loss totaled SEK -4,466,286 (-3,641,800). Loss for the period totaled S... |
| 10.08.2023 | Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program | Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program
Thu, Aug 10, 2023 11:00 CET Report this content
Gothenburg, August 10, 2023 - Elicera Therapeutics AB (publ) (“Eli... |
| 11.07.2023 | Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform | Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform
Tue, Jul 11, 2023 08:57 CET Report this content
Gothenburg, July 11, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage... |
| 29.05.2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!
Mon, May 29, 2023 09:45 CET Report this content
It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| 16.05.2023 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023
Tue, May 16, 2023 08:09 CET Report this content
First quarter (January-March 2023) Operating profit/loss totaled SEK -2,265,857 (-4,741,051). Loss for the period totale... |
| 28.04.2023 | Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study) | Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study)
Fri, Apr 28, 2023 15:47 CET Report this content
Gothenburg, April 28, 2023 - Elic... |
| 17.04.2023 | Elicera Therapeutics publishes the annual report for 2022 | Elicera Therapeutics publishes the annual report for 2022
Mon, Apr 17, 2023 15:09 CET Report this content
Elicera Therapeutics publishes the annual report for 2022
Gothenburg, April 17, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a c... |
| 06.03.2023 | Erik Penser Bank initiates coverage on Elicera Therapeutics | Erik Penser Bank initiates coverage on Elicera Therapeutics
Mon, Mar 06, 2023 12:23 CET Report this content
Elicera Therapeutics AB (publ) has entered into an agreement with Erik Penser Bank regarding coverage. The initial analysis can be r... |
| 01.03.2023 | Elicera Therapeutics hires Erik Penser Bank as market maker | Elicera Therapeutics hires Erik Penser Bank as market maker
Wed, Mar 01, 2023 08:09 CET Report this content
Elicera Therapeutics AB (publ) announced today that it has entered into an agreement with Erik Penser Bank regarding market making.
... |
| 17.02.2023 | Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022 | Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022
Fri, Feb 17, 2023 08:08 CET Report this content
Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022
Fourth quarter (October-December 2022) O... |
| 07.02.2023 | Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives | Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives
Tue, Feb 07, 2023 08:34 CET Report this content
Gothenburg, February 7, 2023 - Elicera Therapeutics... |
| 26.01.2023 | Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma | Elicera Therapeutics submits Clinical Trial Application to evaluate its CAR T-cell therapy in B-cell lymphoma
Thu, Jan 26, 2023 09:47 CET Report this content
Gothenburg, January 26, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clini... |
| 23.01.2023 | Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3 | Elicera Therapeutics continues phase I/IIa study with oncolytic virus as planned, following safety review in cohort 3
Mon, Jan 23, 2023 16:01 CET Report this content
Gothenburg, January 23, 2022 - Elicera Therapeutics AB (publ) (“Elicera”),... |
| 07.12.2022 | Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston | Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston
Wed, Dec 07, 2022 15:30 CET Report this content
Gothenburg... |
| 18.11.2022 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022
Fri, Nov 18, 2022 08:07 CET Report this content
Third quarter (July-September 2022) Operating profit/loss totaled SEK -7,028,100 (-6,753,799). Loss for the period t... |
| 16.11.2022 | Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research | Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research
Wed, Nov 16, 2022 08:30 CET Report this content
Gothenburg, November 16, 2022 - Elicera Therapeutics A... |
| 03.11.2022 | Nomination Committee for Elicera Therapeutics appointed | Nomination Committee for Elicera Therapeutics appointed
Thu, Nov 03, 2022 16:31 CET Report this content
Gothenburg, November 3, 2022 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation... |
| 22.08.2022 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022
Mon, Aug 22, 2022 08:06 CET Report this content
Second quarter (April-June 2022) Operating profit/loss totaled SEK -3,641,800 (-1,818,751). Loss for the period totaled S... |
| 12.08.2022 | Elicera Therapeutics announces participation in several industry and partnering conferences | Elicera Therapeutics announces participation in several industry and partnering conferences
Fri, Aug 12, 2022 13:30 CET Report this content
Gothenburg, August 12, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and ... |
| 02.06.2022 | Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301 | Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301
Thu, Jun 02, 2022 08:30 CET Report this content
Gothenburg, June 2, 2022 - Elicera Therapeutics ... |
| 27.04.2022 | Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action | Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action
Wed, Apr 27, 2022 08:30 CET Report this content
Gothenburg, April 27, 2022 - Elicera Therape... |
| 26.04.2022 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022
Tue, Apr 26, 2022 08:02 CET Report this content
First quarter (January-March 2022) Operating profit/loss totaled SEK -4,741,051 (-2,404,551). Loss for the period totale... |
| 04.04.2022 | Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies | Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies
Mon, Apr 04, 2022 17:00 CET Report this content
Gothenb... |
| 24.02.2022 | Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022 | Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022
Thu, Feb 24, 2022 15:30 CET Report this content
Gothenburg, February 24, 2022 - Elicera Therapeutics AB (publ) (“Elicera... |
| 04.02.2022 | Elicera Therapeutics publishes annual report for 2021 | Elicera Therapeutics publishes annual report for 2021
Fri, Feb 04, 2022 15:29 CET Report this content
Gothenburg, January 14, 2022 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncolog... |
| 25.01.2022 | Elicera Therapeutics AB (publ) Interim Report 1 January - 31 December 2021 | Fourth quarter (October-December 2021)
* Operating loss totaled SEK -2,142,267 (-2,596,526).
* Loss for the period totaled SEK -2,142,267 (-2,596,256).
* Cash flow from operating activities totaled SEK -879,846 (-782,625).
* Earnings per sh... |
| 25.01.2022 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021 | Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021 Tue, Jan 25, 2022 08:04 CET
Fourth quarter (October–December 2021)
* Operating loss totaled SEK -2,142,267 (-2,596,526).
* Loss for the period totaled SEK -2,142,267... |
| 18.01.2022 | Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process | Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process Tue, Jan 18, 2022 13:40 CET
Gothenburg, January 18, 2021 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical st... |
| 14.01.2022 | The Nomination Committee for Elicera Therapeutics proposes re-election of Board | The Nomination Committee for Elicera Therapeutics proposes re-election of Board Fri, Jan 14, 2022 08:12 CET
Gothenburg, January 14, 2022 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-o... |
| 14.01.2022 | The Nomination Committee for Elicera Therapeutics proposes re-election of Board | Gothenburg, January 14, 2022 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncological treatments focused on CAR T-cells and oncolytic viruses, announces that the nomination committee ... |
| 05.01.2022 | Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum | Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum Wed, Jan 05, 2022 08:00 CET
Gothenburg, January 5, 2021 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene the... |
| 15.12.2021 | Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201 | Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201 Wed, Dec 15, 2021 10:00 CET
Gothenburg, December 15, 2021 - Elicera Therapeutics AB (publ) (“E... |
| 18.11.2021 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021 | Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021 Thu, Nov 18, 2021 08:45 CET
Third quarter (July–September 2021)
Operating loss totaled SEK -6,753,799 (-216,550).
Loss for the period totaled SEK -6,753,799 (-211,1... |
